Amarin focused on CV disease to pump new life into company
24 February 2010
Simon Varcoe
Please Login to read the full article.
24 February 2010
Simon Varcoe
simon.varcoe@informa.com
The fundraising that saved Amarin from financial woes last years appear to have given the company a new lease of life. Its interim CEO Dr Declan Doogan told Scrip of his confidence for the company's future.
Since Amarin terminated the development of its lead drug candidate AMR101...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Omthera trials fish oil pill Epanova with statins, hoping for 2012 filing in high TG
- Amarin gains 'rare' 3rd SPA with US FDA for fish oil pill CV study
- Competition looms for Mochida as Takeda files ProNova's omega-3 product in Japan
- With fish oil pill US NDA submitted, Amarin could be acquisition target
ANALYSIS
Other Informa Analysis
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
